Hem/Onc Roundup: Lung Cancer Screening Low for High-Risk Individuals, Being Overweight Linked to Prostate Cancer, and more

Here are the top stories covered by DocWire News this week in the Hematology & Oncology section. This week, the U.S. Food and Drug Administration (FDA) approved a new treatment for multiple myeloma (MM), a study found that being overweight is linked to prostate cancer, and more.

A new study which appeared in Annals of Oncology study links being overweight in middle age and later adulthood to a greater risk of developing advanced prostate cancer.

A study published in Cancer Epidemiology, Biomarkers & Prevention found that a breast cancer diagnosis in young women creates a financial hardship, leading to employment decisions that are heavily influenced by the need to maintain health insurance coverage.

Current and former smokers have an increased risk for developing lung cancer compared to the general population. For this reason, the U.S. Preventive Services Task Force recommends that certain people undergo special lung cancer screenings. Despite these recommendations and the known risk factors, seven in eight patients at high risk for developing the disease neglect to get screened.

The FDA approved Sarclisa® (isatuximab-irfc) in combination with pomalidomide and dexamethasone for adults with MM who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor.

In case you missed it, more hem/onc headlines are featured below: